September 06, 2025

Get In Touch

Fibrosis-4 Stage Of Liver Fibrosis Linked With CV Events In ACS Patients Regardless Of Diabetes Status

Study on Liver Fibrosis and Cardiovascular Risk

China: Liver Fibrosis and Cardiovascular Risk in ACS Patients

Liver fibrosis staged by the Fibrosis-4 (FIB-4) index corresponds to an increased risk of myocardial infarction, MACCE, and mortality in acute coronary syndrome (ACS) patients who underwent PCI independent of diabetes status, a recent study has shown. However, it was not associated with stroke and bleeding events.

The findings, published in Diabetes Research and Clinical Practice, suggest that FIB-4 may be helpful in risk stratification of ACS patients independent of the presence or absence of diabetes.

Jingjing Song and a research team from China and colleagues conducted the study to examine the effect of liver fibrosis, assessed by the Fibrosis-4 index, on cardiovascular events in patients with the acute coronary syndrome with and without type 2 diabetes mellitus (T2DM).

For this purpose, the researchers analyzed 6563 ACS patients undergoing PCI. The participants were divided into three groups based on the literature-based FIB-4 cut-offs: < 1.45, 1.45-3.25, and ≥3.25.

Key Findings

  • During the median 2.4-year follow-up, 270 major adverse cardiac and cerebrovascular events and 194 major bleeding were recorded.
  • Intermediate or high FIB-4 scores were significantly associated with an elevated risk of MACCE, mortality, and myocardial infarction but not related to ischemic stroke and major bleeding.
  • Further restricted cubic spline analysis showed that FIB-4 as a continuous variable was positively associated with increased adjusted risk of MACCE.
  • The results were consistent in subgroups with and without type 2 diabetes.

Liver fibrosis assessed by the FIB-4 index was shown to be linked with myocardial infarction, mortality, and MACCE but not bleeding events and stroke in acute coronary syndrome patients, regardless of type 2 diabetes status.

"The FIB-4 index is useful to improve risk stratification for ischemic cardiac events in ACS patients," the authors wrote. "The study prompted liver fibrosis screening with non-invasive indices in ACS patients with or without type 2 diabetes to identify high-risk patients and help decision-making in clinical practice."

Reference

The study titled "Fibrosis-4 stage of liver fibrosis predicts cardiovascular outcomes in acute coronary syndrome patients with and without type 2 diabetes mellitus" was published in Diabetes Research and Clinical Practice. DOI: https://doi.org/10.1016/j.diabres.2022.110206

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!